

# Shireen Kassam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5350246/publications.pdf>

Version: 2024-02-01

38  
papers

317  
citations

932766

10  
h-index

940134

16  
g-index

38  
all docs

38  
docs citations

38  
times ranked

561  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating nutrition education interventions for medical students: A rapid review. <i>Journal of Human Nutrition and Dietetics</i> , 2022, 35, 861-871.	1.3	11
2	Guidelines for the management of mature T-cell and natural killer-cell lymphomas (excluding cutaneous) Tj ETQq0 0 0 rgBT /Overlock 10 196, 507-522.	1.2	12
3	Guideline for the first-line management of Classical Hodgkin Lymphoma – A British Society for Haematology guideline. <i>British Journal of Haematology</i> , 2022, 197, 558-572.	1.2	14
4	Managing Psoriatic Arthritis With a Whole Food Plant-Based Diet: A Case Study. <i>American Journal of Lifestyle Medicine</i> , 2021, 15, 402-406.	0.8	7
5	Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. <i>Leukemia</i> , 2021, 35, 3223-3231.	3.3	33
6	Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients – A British Society for Haematology Guideline. <i>British Journal of Haematology</i> , 2021, 193, 727-740.	1.2	16
7	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	0.8	37
8	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	2.5	24
9	A phase I/II study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. <i>Blood Advances</i> , 2021, 5, 4073-4082.	2.5	9
10	An audit on the diagnosis of primary CNS lymphoma. <i>Neuro-Oncology</i> , 2021, 23, iv24-iv25.	0.6	0
11	Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial. <i>Blood</i> , 2021, 138, 2492-2492.	0.6	4
12	It's time for healthcare professionals to demand a plant-based food system. <i>British Journal of General Practice</i> , 2021, 71, 554-554.	0.7	3
13	Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. <i>British Journal of Haematology</i> , 2020, 190, 394-404.	1.2	27
14	Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study. <i>Blood</i> , 2020, 136, 34-35.	0.6	0
15	Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance. <i>Blood</i> , 2020, 136, 1-2.	0.6	2
16	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. <i>Blood</i> , 2020, 136, 49-50.	0.6	1
17	Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
18	The Burkitt Lymphoma International Prognostic Index (BL-IPI). <i>Blood</i> , 2020, 136, 46-49.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2019, 134, 761-761.	0.6	9
20	Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort. <i>Blood</i> , 2019, 134, 4566-4566.	0.6	3
21	A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial. <i>Blood</i> , 2019, 134, 2879-2879.	0.6	0
22	Results of a multicentre <sc>UK</sc>-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma. <i>British Journal of Haematology</i> , 2018, 181, 555-559.	1.2	13
23	A retrospective analysis of post-transplant lymphoproliferative disorder following liver transplantation. <i>European Journal of Haematology</i> , 2018, 100, 98-103.	1.1	6
24	HHV8-associated lymphoproliferative disorder in the peripheral blood. <i>Blood</i> , 2018, 131, 2868-2868.	0.6	1
25	The iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 402-402.	0.6	2
26	Prognostic and Predictive Impact of Small PNH Clones in a Large Cohort of Patients with Myelodysplastic Syndromes and Aplastic Anemia: A Single-Center Experience. <i>Blood</i> , 2018, 132, 3870-3870.	0.6	4
27	Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival. <i>Blood</i> , 2018, 132, 572-572.	0.6	0
28	Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2051-2056.	0.6	7
29	Results of a multicentre <sc>UK</sc>-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. <i>British Journal of Haematology</i> , 2017, 179, 471-479.	1.2	20
30	Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids. <i>Journal of Clinical and Translational Endocrinology</i> , 2017, 9, 18-20.	1.0	8
31	Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017, 130, 887-887.	0.6	22
32	<sc>ALK</sc>-positive large B-cell lymphoma with strong <sc>CD</sc>30 expression; a diagnostic pitfall and resistance to brentuximab and crizotinib. <i>Histopathology</i> , 2016, 69, 880-882.	1.6	12
33	A rare cause of lymphadenopathy â€“ Rosai-Dorfman disease in a HIV-positive Ugandan woman. <i>International Journal of STD and AIDS</i> , 2016, 27, 1123-1125.	0.5	5
34	Amelanotic melanoma in the bone marrow. <i>Blood</i> , 2016, 128, 313-313.	0.6	3
35	Diffuse Large B-Cell Lymphoma (DLBCL) Tumor Cells Reprogram Lymphatic Fibroblasts into Cancer-Associated Fibroblasts (CAFs) That Contribute to Tumor Microenvironment (TME)-Driven Immune Privilege. <i>Blood</i> , 2015, 126, 1474-1474.	0.6	2
36	Autologous Stem Cell Transplantation Achieves Long-Term Survival in a Selected CNS Lymphoma Population. <i>Blood</i> , 2014, 124, 1197-1197.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Lymphoma in the immunosuppressed. , 0 , 273-285.		0
38	The Role of Nutrition in Cancer Prevention - Should You Listen to Your Doctor or Influencer?. American Journal of Lifestyle Medicine, 0 , 155982762211123.	0.8	0